• Pulmonary Arterial Remodeling and RV Afterload

  2026-09-19

  This study uses a subject-specific one-dimensional fluid–structure interaction model to separate how distal resistance and proximal arterial stiffness shape pulmonary hypertension hemodynamics. Its main finding is that increased distal resistance most strongly raises maximum main pulmonary artery pressure, whereas reduced compliance markedly increases characteristic impedance, providing a quantitative basis for more targeted interpretation of right ventricular afterload.

• Vidarabine Monohydrate in Cell Assays

  2026-09-18

  Learn how Vidarabine monohydrate, SKU C6377, can support more interpretable antiviral, proliferation, viability, and cytotoxicity workflows. This scenario-based guide focuses on solubility control, vehicle matching, assay design, data interpretation, and practical product selection.

• Aprotinin for RBC Membrane and Protease Assays

  2026-09-18

  Aprotinin connects reversible serine protease inhibition with practical workflows for red blood cell membrane mechanics, fibrinolysis studies, and cardiovascular surgery blood-management research. This guide translates multiscale membrane findings into controlled assay designs, dosing screens, and troubleshooting decisions without overstating clinical or mechanistic evidence.

• (-)-Arctigenin Workflows for NF-κB and MEK1 Studies

  2026-09-17

  Use (-)-Arctigenin as a pharmacological probe to connect inflammatory signaling, macrophage–tumor communication, and MEK1 biology in reproducible bench workflows. Its DMSO compatibility and nanomolar activity support dose-response experiments, while careful controls help distinguish NF-κB pathway modulation from nonspecific cytotoxicity.

• Phillygenin in Diabetic Nephropathy: Mechanistic Evidence

  2026-09-17

  The reference study shows that phillygenin protects against diabetic kidney injury by suppressing TLR4/MyD88/NF-κB-mediated inflammation and restoring PI3K/AKT/GSK3β-associated survival signaling. Its integrated podocyte, transcriptomic, biochemical, and db/db mouse data provide a preclinical framework for evaluating phillygenin as a candidate intervention in diabetic nephropathy.

• Thymoquinone Protects Against Doxorubicin Cardiotoxicity

  2026-09-16

  A 2025 mouse study reports that thymoquinone attenuates doxorubicin-induced cardiac injury while improving antioxidant defenses and mitochondrial morphology. Its findings connect Nrf2/HO-1 signaling with reduced ferroptosis-related damage, offering a mechanistic framework for refining cardiotoxicity models without yet establishing clinical or antitumor efficacy.

• Cyclosporin A: Assays and Workflow Optimization

  2026-09-16

  Build reproducible Cyclosporin A workflows that connect cyclophilin–calcineurin signaling with mitochondrial permeability transition pore inhibition. Practical dose ranges, variant comparisons, and troubleshooting guidance help distinguish genuine pathway effects from exposure, vehicle, and organelle-quality artifacts.

• BOP Reagent for Peptide and Prodrug Workflows

  2026-09-15

  BOP reagent combines practical carboxyl group activation with solution-phase flexibility for peptide, phenyl ester, and linker synthesis. This guide translates that chemistry into a controlled workflow inspired by a carrier-free, ROS-responsive oral squamous cell carcinoma prodrug study.

• Abiraterone Acetate in 3D Prostate Models

  2026-09-15

  Abiraterone acetate can reveal how androgen biosynthesis inhibition behaves in patient-derived prostate spheroids. This evidence-focused guide explains mechanism, assay design, prodrug interpretation, and why a negative ex vivo response may still be scientifically informative.

• CCK-8 Suppresses IgG1 in LPS-Activated B Cells

  2026-09-14

  The 2011 reference study showed that sulfated CCK-8 suppresses proliferation, IgG1 mRNA expression, and IgG1 production in LPS-activated mouse B cells, with the principal effect attributed to CCK2R signaling. Its mechanistic contribution was to connect this humoral immune effect with time-dependent regulation of Blimp1, Pax5, Xbp1, and Bcl6, providing a framework for studying CCK-mediated immune deactivation.

• BML-277: Chk2 Inhibition in Genome Stability

  2026-09-14

  BML-277 is a potent, selective Chk2 inhibitor for dissecting DNA damage signaling. This article translates nuclear cGAS–Chk2–TRIM41 findings into practical assay strategies while clarifying implications for T-cell radioprotection and cancer research.

• JNK-IN-7: Mapping Pathogen-Driven Apoptosis

  2026-09-13

  JNK-IN-7 is a selective JNK inhibitor for resolving how pathogen morphology, innate immune signaling, and apoptotic commitment intersect. This article translates Candida krusei findings into a rigorous assay strategy while defining the compound’s mechanistic scope, controls, and handling requirements.

• H. pylori–HNF4A Methylation Drives Gastric Cancer

  2026-09-12

  The 2025 reference study identifies H. pylori-induced promoter hypermethylation of HNF4A as a mechanistic link between infection, loss of gastric epithelial polarity, TGFβ-associated EMT signaling, and gastric cancer progression. Its integrated clinical, single-cell, methylation, perturbation, and rescue experiments provide a framework for testing infection-associated epigenetic silencing in gastric cancer models.

• Preserving Phosphosignals in Liver Regeneration

  2026-09-11

  A mechanistic and translational perspective on how phosphatase control strengthens studies of SPP2, BMP signaling, liver regeneration, and phosphoproteomic analysis. The article positions Phosphatase Inhibitor Cocktail 1 (100X in DMSO) as a sample-integrity tool rather than a substitute for biological validation.

• Adenosine Triphosphate (ATP) in Metabolic Assays

  2026-09-11

  Learn how to use ATP as both an experimental reagent and an energy-state readout in workflows studying OGDH, mitochondrial proteostasis, and purinergic signaling. This guide pairs practical ATP handling with assay designs that distinguish altered metabolism from extracellular receptor effects.

8743 records 1/583 page Next 12345 下5页 Last page